1. Diehl V. Hodgkin’s disease–from pathology specimen to cure. N Engl J Med. 2007;357:1968–71.
2. Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). National Cancer Institute. Bethesda, MD, . SEER Cancer Statistics Review, 1975–2010. p. based on November 2012 SEER data submission, posted to the SEER web site, http://seer.cancer.gov/csr/1975_2010/ .
3. Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14:943–52.
4. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.
5. NCCN Clinical Practice Guidelines in Oncology™ Hodgkin Lymphoma v.1.2013. National Comprehensive Cancer Network; 2013. http://www.nccn.org/professionals/physician_gls/PDF/hodgkins .